This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
respiratory syndrome | 21544 |
acute respiratory | 21529 |
severe acute | 18071 |
novel coronavirus | 13801 |
syndrome coronavirus | 10716 |
coronavirus disease | 10454 |
spike protein | 6077 |
public health | 5142 |
sars coronavirus | 4903 |
cord uid | 4563 |
doc id | 4563 |
immune response | 4396 |
middle east | 4200 |
severe covid | 4058 |
converting enzyme | 4037 |
east respiratory | 3990 |
author funder | 3860 |
granted medrxiv | 3841 |
viral rna | 3636 |
copyright holder | 3600 |
clinical characteristics | 3582 |
respiratory tract | 3429 |
viral load | 3375 |
health care | 3328 |
respiratory distress | 3273 |
version posted | 3194 |
hong kong | 3137 |
world health | 3040 |
infectious diseases | 2975 |
clinical trials | 2946 |
health organization | 2838 |
amino acid | 2818 |
systematic review | 2762 |
distress syndrome | 2739 |
coronavirus infection | 2678 |
cytokine storm | 2672 |
united states | 2637 |
risk factors | 2613 |
cov infection | 2596 |
peer review | 2590 |
immune responses | 2583 |
viral infection | 2561 |
epithelial cells | 2547 |
nucleic acid | 2497 |
intensive care | 2448 |
immune system | 2405 |
human coronavirus | 2401 |
hospitalized patients | 2385 |
critically ill | 2330 |
clinical features | 2300 |
infected patients | 2246 |
viral replication | 2241 |
virus infection | 2227 |
host cell | 2214 |
patients infected | 2173 |
sars patients | 2148 |
rights reserved | 2133 |
made available | 2107 |
spike glycoprotein | 2099 |
viral infections | 2069 |
influenza virus | 1981 |
lung injury | 1958 |
infectious disease | 1948 |
international license | 1939 |
binding domain | 1937 |
healthcare workers | 1926 |
medrxiv preprint | 1925 |
new coronavirus | 1884 |
cohort study | 1881 |
neutralizing antibodies | 1846 |
innate immune | 1833 |
type i | 1829 |
receptor binding | 1806 |
clinical trial | 1792 |
confirmed cases | 1773 |
ill patients | 1754 |
convalescent plasma | 1736 |
infection control | 1719 |
disease control | 1669 |
host cells | 1626 |
respiratory failure | 1615 |
ace expression | 1614 |
pregnant women | 1593 |
severe disease | 1592 |
symptom onset | 1577 |
coronavirus spike | 1571 |
sars cov | 1563 |
cl pro | 1555 |
care workers | 1552 |
cell entry | 1551 |
mechanical ventilation | 1544 |
gene expression | 1525 |
disease severity | 1521 |
incubation period | 1521 |
human ace | 1513 |
ace receptor | 1513 |
antiviral activity | 1482 |
may also | 1472 |
infected cells | 1470 |
lopinavir ritonavir | 1465 |
rna polymerase | 1465 |
coronavirus pneumonia | 1448 |
main protease | 1436 |
amino acids | 1434 |
human coronaviruses | 1422 |
antibody responses | 1404 |
clinical course | 1400 |
rna viruses | 1397 |
viral entry | 1395 |
case series | 1392 |
chest ct | 1390 |
inflammatory cytokines | 1389 |
respiratory disease | 1383 |
upper respiratory | 1370 |
chain reaction | 1330 |
respiratory symptoms | 1315 |
care unit | 1311 |
structural proteins | 1302 |
mortality rate | 1295 |
polymerase chain | 1282 |
nucleocapsid protein | 1281 |
protective equipment | 1265 |
nervous system | 1264 |
tested positive | 1246 |
increased risk | 1246 |
sars outbreak | 1222 |
performed using | 1209 |
inflammatory response | 1197 |
kcal mol | 1195 |
like protease | 1193 |
confirmed covid | 1191 |
severe cases | 1179 |
associated coronavirus | 1167 |
personal protective | 1156 |
ebola virus | 1153 |
coronavirus infections | 1145 |
endothelial cells | 1139 |
membrane fusion | 1134 |
cancer patients | 1133 |
active site | 1130 |
animal models | 1129 |
authors declare | 1126 |
social distancing | 1124 |
virus replication | 1114 |
without permission | 1109 |
reuse allowed | 1105 |
allowed without | 1105 |
viral shedding | 1105 |
new york | 1103 |
angiotensin ii | 1103 |
lower respiratory | 1103 |
fatality rate | 1098 |
mental health | 1085 |
neutralizing antibody | 1064 |
binding affinity | 1051 |
reverse transcription | 1038 |
crystal structure | 1035 |
respiratory viruses | 1027 |
case report | 1020 |
acute lung | 1012 |
cell lines | 1009 |
respiratory syncytial | 998 |
among patients | 995 |
immune cells | 994 |
antiviral drugs | 988 |
general population | 976 |
nasopharyngeal swab | 974 |
previous studies | 966 |
viral genome | 963 |
protease inhibitor | 963 |
viral proteins | 962 |
cell responses | 962 |
monoclonal antibodies | 961 |
molecular docking | 961 |
control measures | 959 |
infected pneumonia | 957 |
syncytial virus | 957 |
monoclonal antibody | 952 |
viral loads | 949 |
dependent rna | 946 |
cell culture | 942 |
heart failure | 930 |
serum samples | 929 |
vaccine development | 928 |
significantly higher | 926 |
coronavirus associated | 925 |
global health | 920 |
binding site | 913 |
angiotensin converting | 912 |
high risk | 906 |
clinical symptoms | 905 |
close contact | 904 |
room temperature | 901 |
first case | 900 |
present study | 899 |
higher risk | 881 |
important role | 878 |
human transmission | 875 |
statistically significant | 872 |
cell types | 867 |
cardiovascular disease | 866 |
retrospective cohort | 865 |
test results | 861 |
infected individuals | 860 |
cell surface | 849 |
recent study | 844 |
peripheral blood | 844 |
respiratory infections | 839 |
cov spike | 835 |
supplementary table | 833 |
antibody response | 833 |
spike proteins | 831 |
avian influenza | 828 |
protease inhibitors | 826 |
risk factor | 822 |
hubei province | 818 |
rna virus | 818 |
molecular dynamics | 815 |
cleavage site | 815 |
virus entry | 814 |
stem cells | 813 |
severe respiratory | 803 |
dendritic cells | 793 |
drug repurposing | 792 |
orf ab | 787 |
observational study | 785 |
central nervous | 785 |
corona virus | 785 |
drug discovery | 784 |
transmission dynamics | 781 |
high levels | 781 |
functional receptor | 781 |
clinical outcomes | 776 |
control group | 774 |
human respiratory | 766 |
bat origin | 761 |
reactive protein | 758 |
immunodeficiency virus | 756 |
viral particles | 756 |
saudi arabia | 752 |
stranded rna | 751 |
closely related | 749 |
gastrointestinal symptoms | 741 |
informed consent | 741 |
nasopharyngeal swabs | 740 |
mg ml | 737 |
clinical manifestations | 736 |
igg antibodies | 735 |
en el | 734 |
controlled trial | 734 |
contact tracing | 732 |
receptor ace | 732 |
descriptive study | 727 |
large number | 724 |
pneumonia outbreak | 722 |
specific antibodies | 722 |
hydrogen bonds | 721 |
sars epidemic | 720 |
clinical studies | 717 |
case fatality | 717 |
innate immunity | 715 |
vero cells | 713 |
severe pneumonia | 713 |
pl pro | 712 |
side effects | 712 |
previously described | 708 |
human immunodeficiency | 707 |
electron microscopy | 697 |
vertical transmission | 689 |
diabetes mellitus | 689 |
target cells | 688 |
another study | 686 |
angiotensin system | 686 |
time rt | 685 |
type ii | 684 |
pcr testing | 680 |
randomized clinical | 679 |
coronavirus sars | 678 |
transplant recipients | 677 |
retrospective study | 674 |
respiratory infection | 672 |
asymptomatic patients | 668 |
structural basis | 668 |
serine protease | 667 |
cell epitopes | 666 |
positive patients | 662 |
health emergency | 662 |
cov cl | 661 |
genome sequence | 659 |
free energy | 656 |
organ failure | 656 |
global pandemic | 654 |
recent studies | 654 |
also found | 653 |
nk cells | 653 |
least one | 651 |
pcr test | 650 |
adaptive immune | 647 |
hepatitis virus | 645 |
close contacts | 645 |
significant difference | 644 |
total number | 644 |
cell line | 643 |
sample size | 641 |
even though | 640 |
factors associated | 639 |
blood pressure | 638 |
cell death | 635 |
positive results | 626 |
sars virus | 623 |
family members | 622 |
outbreak associated | 621 |
randomized controlled | 620 |
respiratory illness | 619 |
mg kg | 619 |
clinical presentation | 614 |
kidney injury | 611 |
emerging infectious | 610 |
lung tissue | 610 |
probable bat | 609 |
cytokine release | 609 |
clinical samples | 607 |
airborne transmission | 604 |
disease progression | 602 |
hydrogen bond | 601 |
early stage | 600 |
virus disease | 600 |
within days | 599 |
emergency department | 597 |
potential therapeutic | 596 |
rna synthesis | 596 |
host immune | 595 |
respiratory droplets | 594 |
antiviral drug | 592 |
binding energy | 592 |
i interferon | 591 |
acid residues | 591 |
several studies | 590 |
rna extraction | 588 |
necrosis factor | 587 |
influenza viruses | 585 |
sars cases | 584 |
virtual screening | 584 |
coronavirus replication | 583 |
reverse transcriptase | 578 |
two groups | 576 |
medical staff | 576 |
time pcr | 576 |
two patients | 576 |
proinflammatory cytokines | 576 |
patients may | 575 |
ang ii | 573 |
national health | 571 |
sore throat | 570 |
respiratory specimens | 569 |
data analysis | 569 |
oxidative stress | 567 |
adverse events | 567 |
multiple organ | 566 |
approved drugs | 565 |
years old | 564 |
may lead | 563 |
viral clearance | 562 |
confirmed sars | 558 |
common cold | 558 |
patients admitted | 557 |
open reading | 556 |
clinical specimens | 556 |
mortality rates | 555 |
related coronavirus | 555 |
highly pathogenic | 554 |
clinically proven | 553 |
clinical data | 552 |
envelope protein | 548 |
person transmission | 548 |
pulmonary disease | 547 |
case reports | 547 |
phylogenetic analysis | 547 |
lung cancer | 546 |
competing interests | 544 |
cell membrane | 544 |
class i | 543 |
human cells | 543 |
human monoclonal | 542 |
data collection | 541 |
rheumatoid arthritis | 540 |
adverse effects | 538 |
pdb id | 538 |
ace protein | 537 |
cell receptor | 537 |
entry depends | 537 |
pcr assay | 536 |
hospital admission | 536 |
wide range | 535 |
tract infections | 535 |
negative results | 535 |
critical care | 534 |
ct values | 533 |
median age | 533 |
pandemic influenza | 532 |
one patient | 532 |
acute kidney | 530 |
coronavirus outbreak | 530 |
hand hygiene | 530 |
data suggest | 529 |
ng ml | 528 |
stem cell | 528 |
human airway | 527 |
proven protease | 526 |
viral pneumonia | 525 |
south korea | 525 |
myocardial injury | 523 |
posted may | 523 |
virus infections | 522 |
ncov infection | 521 |
liver injury | 519 |
genome sequences | 519 |
previously reported | 518 |
dry cough | 517 |
rhesus macaques | 516 |
pediatric patients | 515 |
infection prevention | 515 |
inflammatory responses | 514 |
also observed | 514 |
mouse model | 514 |
sequence alignment | 513 |
widely used | 513 |
severe patients | 512 |
computed tomography | 511 |
terminal domain | 509 |
endoplasmic reticulum | 508 |
patients hospitalized | 508 |
respiratory virus | 506 |
including sars | 506 |
two different | 505 |
tumor necrosis | 505 |
mild symptoms | 505 |
posted september | 503 |
patients treated | 503 |
symptomatic patients | 500 |
neurological manifestations | 500 |
diagnostic tests | 500 |
mouse hepatitis | 499 |
study showed | 498 |
creative commons | 498 |
protective immunity | 496 |
also known | 495 |
binding sites | 494 |
statistical analysis | 494 |
highly conserved | 493 |
may cause | 493 |
clinical practice | 492 |
ace receptors | 491 |
significant differences | 489 |
swab samples | 488 |
cardiac injury | 488 |
china clinical | 487 |
mesenchymal stem | 485 |
zika virus | 485 |
study clinical | 481 |
one study | 480 |
heart disease | 479 |
airway epithelial | 479 |
icu patients | 478 |
posted august | 477 |
positive sars | 476 |
early stages | 476 |
antiviral agents | 476 |
results suggest | 475 |
nlrp inflammasome | 475 |
nucleic acids | 475 |
different types | 473 |
cov nsp | 473 |
taken together | 473 |
signaling pathway | 472 |
septic shock | 470 |
alveolar damage | 468 |
family cluster | 467 |
supplementary material | 467 |
type diabetes | 467 |
ct scan | 466 |
icu admission | 465 |
direct contact | 465 |
antibody titers | 464 |
growth factor | 464 |
spectrum antiviral | 464 |
samples collected | 462 |
human lung | 461 |
copies ml | 460 |
oxygen saturation | 459 |
blood samples | 458 |
posted june | 458 |
myocardial infarction | 457 |
disease caused | 457 |
los pacientes | 456 |
em structure | 456 |
receptor blockers | 456 |
life cycle | 456 |
multiple sclerosis | 456 |
herpes simplex | 455 |
results showed | 455 |
tested negative | 455 |
first step | 454 |
also reported | 454 |
virus type | 454 |
protein interaction | 452 |
york city | 452 |
novel human | 451 |
significantly lower | 451 |
may play | 451 |
drug administration | 450 |
suspected covid | 450 |
dengue virus | 450 |
negative control | 448 |
face masks | 448 |
membrane protein | 448 |
commonly used | 446 |
endothelial cell | 445 |
like receptor | 444 |
animal model | 443 |
current pandemic | 441 |
protein expression | 439 |
severe sars | 438 |
lung disease | 437 |
clinical management | 436 |
may contribute | 436 |
bone marrow | 435 |
respiratory viral | 435 |
viral spike | 434 |
molecular weight | 434 |
higher levels | 433 |
per day | 433 |
patients without | 433 |
protein structure | 433 |
cell fusion | 432 |
kidney disease | 432 |
pacientes con | 431 |
respiratory diseases | 430 |
real time | 430 |
western blot | 429 |
detect sars | 429 |
receptor recognition | 428 |
logistic regression | 428 |
fusion protein | 427 |
cell rna | 426 |
infectious virus | 426 |
rna genome | 426 |
adult inpatients | 425 |
pulmonary fibrosis | 425 |
protein interactions | 425 |
currently available | 424 |
diffuse alveolar | 424 |
reported cases | 423 |
west nile | 423 |
may provide | 423 |
suspected cases | 420 |
therapeutic options | 419 |
severe illness | 418 |
united kingdom | 416 |
reproduction number | 416 |
neurological symptoms | 416 |
enveloped viruses | 415 |
infect dis | 415 |
adult patients | 415 |
signaling pathways | 415 |
time reverse | 414 |
key role | 414 |
igg antibody | 414 |
release syndrome | 414 |
treatment options | 414 |
respiratory system | 414 |
commercially available | 413 |
urgent need | 412 |
causative agent | 412 |
nan doi | 412 |
herd immunity | 411 |
health commission | 411 |
crucial role | 410 |
dna vaccine | 410 |
cell response | 410 |
host response | 409 |
virus transmission | 409 |
highly expressed | 408 |
atypical pneumonia | 408 |
high viral | 408 |
interim guidance | 407 |
cov infections | 406 |
virus particles | 406 |
current study | 405 |
patients receiving | 404 |
situation report | 403 |
human sars | 403 |
coronavirus nucleocapsid | 403 |
also showed | 402 |
glass opacities | 402 |
preventive measures | 402 |
vaccine candidates | 402 |
poor prognosis | 402 |
positive cases | 402 |
plasma therapy | 401 |
chinese center | 401 |
alveolar epithelial | 400 |
patient care | 400 |
study group | 400 |
treat covid | 400 |
md simulation | 399 |
natural killer | 399 |
health authorities | 399 |
epidemiological characteristics | 398 |
binding free | 398 |
early phase | 398 |
described previously | 398 |
time points | 398 |
human population | 398 |
positive samples | 397 |
specific antibody | 397 |
million people | 396 |
effective treatment | 396 |
infectious bronchitis | 396 |
high mortality | 395 |
available data | 395 |
cd cd | 394 |
older adults | 394 |
cov replication | 394 |
antiviral therapy | 393 |
infection may | 393 |
age groups | 393 |
molecular mechanisms | 392 |
bronchoalveolar lavage | 392 |
surgical masks | 392 |
plasma membrane | 392 |
chronic obstructive | 391 |
isothermal amplification | 391 |
viral protein | 391 |
two weeks | 391 |
three times | 389 |
van der | 389 |
secondary structure | 388 |
simplex virus | 388 |
clinical signs | 388 |
lateral flow | 388 |
accessory proteins | 387 |
much higher | 387 |
dipeptidyl peptidase | 387 |
lymphocyte count | 386 |
prospective study | 386 |
sequence identity | 385 |
emergency use | 384 |
sars infection | 384 |
nitric oxide | 383 |
genomic rna | 383 |
laboratory findings | 382 |
virus origins | 382 |
patients showed | 381 |
posted july | 381 |
acid sequence | 380 |
viral diseases | 379 |
traditional chinese | 378 |
cytopathic effect | 377 |
obstructive pulmonary | 377 |
drug design | 377 |
viral transmission | 377 |
national institute | 377 |
determine whether | 376 |
sample collection | 376 |
respiratory pathogens | 376 |
tract infection | 375 |
infected mice | 375 |
surface area | 375 |
viral envelope | 375 |
familial cluster | 375 |
many countries | 374 |
index case | 374 |
care units | 374 |
positive control | 374 |
cov rna | 373 |
may help | 373 |
serological tests | 373 |
study design | 372 |
potential role | 371 |
guangdong province | 371 |
intravenous immunoglobulin | 371 |
ischemic stroke | 371 |
study period | 369 |
inhibitory activity | 369 |
conformational changes | 368 |
tissue distribution | 368 |
high level | 368 |
cells expressing | 368 |
days post | 368 |
bat sars | 368 |
lactate dehydrogenase | 367 |
ct findings | 367 |
phase i | 366 |
gold standard | 366 |
flow cytometry | 366 |
inflammatory syndrome | 366 |
healthcare professionals | 365 |
antibody tests | 364 |
calculated using | 364 |
community transmission | 364 |
genome sequencing | 364 |
kawasaki disease | 363 |
health system | 363 |
mass spectrometry | 363 |
genomic characterisation | 362 |
three patients | 362 |
cardiovascular system | 362 |
emerging coronaviruses | 361 |
ethics committee | 361 |
cytokine production | 361 |
may result | 361 |
inhibit sars | 361 |
chinese medicine | 360 |
critical role | 360 |
southern china | 360 |
acute phase | 360 |
i ifn | 360 |
asymptomatic cases | 359 |
standard deviation | 359 |
pcr tests | 359 |
body temperature | 358 |
mg dl | 357 |
prefusion conformation | 356 |
pcr assays | 356 |
tissue damage | 356 |
gastrointestinal tract | 355 |
probable sars | 355 |
en pacientes | 355 |
sialic acid | 355 |
white blood | 354 |
bat coronavirus | 354 |
vaccine candidate | 353 |
pulmonary embolism | 352 |
previous study | 352 |
antiviral effects | 352 |
machine learning | 351 |
coronavirus rna | 351 |
whole blood | 351 |
mild disease | 350 |
transgenic mice | 350 |
thermo fisher | 350 |
medical records | 350 |
reading frame | 349 |
early transmission | 349 |
recently emerged | 349 |
care facilities | 348 |
nile virus | 348 |
adipose tissue | 348 |
specific igg | 348 |
bronchitis virus | 347 |
inflammatory cytokine | 347 |
severe symptoms | 347 |
mean age | 347 |
nosocomial transmission | 346 |
false negative | 346 |
common symptoms | 346 |
linked immunosorbent | 346 |
small molecule | 346 |
age group | 346 |
ill covid | 345 |
epithelial cell | 345 |
confidence interval | 345 |
lung pathology | 345 |
disease transmission | 344 |
small molecules | 344 |
biorxiv doi | 344 |
pathological findings | 344 |
crystal structures | 344 |
humoral immune | 344 |
recovered patients | 343 |
future studies | 343 |
pcr results | 343 |
md simulations | 343 |
spike receptor | 341 |
observational cohort | 341 |
disease course | 340 |
mild covid | 339 |
asymptomatic carriers | 339 |
antiviral treatment | 339 |
therapeutic targets | 339 |
endothelial dysfunction | 338 |
clinical improvement | 338 |
expression levels | 338 |
blood cell | 337 |
first time | 337 |
cell cultures | 337 |
positive test | 335 |
data bank | 335 |
pneumonia associated | 334 |
protease tmprss | 334 |
ace inhibitors | 334 |
structural protein | 334 |
protein data | 334 |
relative humidity | 333 |
coronavirus hku | 333 |
better understand | 332 |
disease outbreaks | 332 |
first reported | 332 |
infectious agents | 332 |
multisystem inflammatory | 332 |
cell type | 331 |
treating covid | 331 |
systemic inflammation | 331 |
vaccine design | 331 |
throat swab | 330 |
lung damage | 330 |
laboratory tests | 330 |
oral transmission | 330 |
cerebrospinal fluid | 330 |
multiple sequence | 330 |
diagnostic testing | 330 |
analysis showed | 329 |
induced lung | 328 |
relatively low | 327 |
elevated levels | 327 |
remains unclear | 327 |
statistical significance | 326 |
antibody levels | 326 |
therapeutic agents | 326 |
macrophage activation | 326 |
rapid spread | 326 |
lung epithelial | 326 |
angiotensinconverting enzyme | 326 |
results indicate | 326 |
controlled trials | 326 |
effectively inhibit | 325 |
university hospital | 325 |
hiv aids | 325 |
small number | 324 |
laboratory testing | 324 |
dis doi | 324 |
expressing cells | 323 |
organ dysfunction | 323 |
force field | 323 |
important lessons | 323 |
infected people | 323 |
infection rate | 322 |
critical illness | 322 |
liver disease | 322 |
may occur | 322 |
oxygen therapy | 322 |
better understanding | 322 |
complete genome | 321 |
nonstructural proteins | 321 |
ncov spike | 321 |
higher mortality | 321 |
new virus | 321 |
coronavirus indicating | 320 |
binding pocket | 320 |
saliva samples | 320 |
protein kinase | 320 |
high affinity | 319 |
findings suggest | 319 |
will need | 319 |
potential risk | 319 |
lung cells | 319 |
two cases | 319 |
see table | 319 |
drug candidates | 319 |
angiotensin receptor | 318 |
respiratory samples | 318 |
binding protein | 318 |
strand rna | 318 |
less likely | 317 |
kidney transplant | 317 |
cardiovascular diseases | 317 |
serological assays | 317 |
human health | 317 |
clinical outcome | 317 |
vitro studies | 317 |
coronavirus nl | 316 |
hospitalized covid | 316 |
influenza pandemic | 316 |
patients received | 315 |
coronavirus main | 315 |
household contacts | 315 |
throat swabs | 314 |
mice infected | 314 |
asymptomatic individuals | 314 |
like particles | 314 |
analyzed using | 314 |
alveolar macrophages | 314 |
inflammatory markers | 312 |
mm nacl | 312 |
venous thromboembolism | 312 |
severe coronavirus | 312 |
sequence analysis | 311 |
patients presenting | 311 |
case definition | 311 |
well plates | 311 |
may increase | 310 |
coronavirus oc | 310 |
mers coronavirus | 310 |
face mask | 310 |
disease outbreak | 309 |
virus rna | 309 |
early diagnosis | 309 |
early detection | 308 |
structural studies | 305 |
clinical findings | 305 |
severely ill | 305 |
rna detection | 305 |
antibody test | 305 |
mononuclear cells | 305 |
virus may | 304 |
acquired pneumonia | 304 |
one case | 304 |
intravascular coagulation | 304 |
cells infected | 304 |
wuhan city | 303 |
control study | 303 |
drug development | 303 |
fusion peptide | 303 |
patient samples | 302 |
extended data | 302 |
blood group | 302 |
health measures | 302 |
ace binding | 302 |
results obtained | 302 |
antibody testing | 301 |
observational studies | 301 |
young children | 301 |
human infection | 301 |
antiviral response | 301 |
inflammatory bowel | 301 |
serum levels | 300 |
drug targets | 300 |
viral nucleic | 300 |
rna sequencing | 300 |
whole genome | 300 |
ion channel | 299 |
hydrogen bonding | 299 |
rna replication | 299 |
dependent enhancement | 298 |
median time | 298 |
hospital stay | 298 |
en los | 298 |
disseminated intravascular | 298 |
ground glass | 298 |
specific cd | 297 |
study reported | 297 |
immunosorbent assay | 297 |
cell activation | 297 |
literature review | 297 |
open access | 296 |
human tissues | 296 |
immune cell | 296 |
nipah virus | 296 |
abdominal pain | 296 |
positive rt | 296 |
review board | 296 |
surgical mask | 295 |
nk cell | 295 |
ace gene | 295 |
rapid detection | 294 |
hemorrhagic fever | 294 |
different countries | 294 |
health systems | 294 |
weight loss | 294 |
current covid | 294 |
infect humans | 293 |
new cases | 293 |
inhibitory effect | 292 |
vaccinia virus | 292 |
north america | 292 |
high prevalence | 292 |
protective effect | 291 |
evidence suggests | 291 |
also used | 291 |
medical center | 291 |
like symptoms | 291 |
international committee | 290 |
cells via | 290 |
institutional review | 290 |
sequencing data | 289 |
publicly available | 289 |
relatively high | 288 |
murine coronavirus | 288 |
posted october | 288 |
lessons learned | 288 |
neurological complications | 288 |
nonstructural protein | 288 |
regression analysis | 288 |
risk assessment | 288 |
human angiotensin | 288 |
positive result | 288 |
therapeutic strategies | 287 |
coronary artery | 287 |
preliminary report | 287 |
bat coronaviruses | 287 |
broad spectrum | 287 |
lung inflammation | 287 |
low levels | 287 |
infection among | 287 |
infected person | 287 |
mediated isothermal | 286 |
mm tris | 286 |
studies showed | 286 |
analysis based | 286 |
angiotensin i | 285 |
seasonal influenza | 285 |
high sensitivity | 285 |
aldosterone system | 285 |
asymptomatic infection | 284 |
human proteins | 284 |
healthcare settings | 284 |
significantly reduced | 284 |
serum antibody | 283 |
first cases | 283 |
adaptive immunity | 283 |
negative pressure | 283 |
false positive | 282 |
cellular immune | 282 |
phylogenetic tree | 282 |
influenza infection | 282 |
days later | 282 |
class ii | 282 |
least two | 282 |
therapeutic target | 281 |
may affect | 281 |
study found | 281 |
indicating person | 281 |
hydrophobic interactions | 281 |
lung tissues | 281 |
side chain | 280 |
highly contagious | 280 |
neutralization assay | 280 |
human cell | 279 |
attack rate | 279 |
general public | 279 |
novel virus | 279 |
previous reports | 279 |
cleavage sites | 279 |
three different | 278 |
recently published | 278 |
current knowledge | 278 |
antiviral effect | 278 |
acid detection | 278 |
medical history | 277 |
cov genome | 277 |
emerged novel | 277 |
reading frames | 277 |
viral respiratory | 277 |
transmissible gastroenteritis | 277 |
study also | 277 |
accepted article | 277 |
viral spread | 277 |
tissue culture | 276 |
scientific community | 276 |
first week | 275 |
natural products | 275 |
health workers | 275 |
igm antibodies | 275 |
chloroquine effectively | 275 |
springer nature | 275 |
animal species | 275 |
understanding sars | 275 |
fda approved | 275 |
mainland china | 274 |
current evidence | 274 |
small intestine | 274 |
associated pneumonia | 274 |
healthy individuals | 273 |
hydrogen peroxide | 273 |
increased levels | 273 |
like receptors | 273 |
novel sars | 273 |
high expression | 273 |
sectional study | 272 |
will also | 272 |
transmission potential | 271 |
neurologic manifestations | 271 |
might also | 271 |
lymph nodes | 271 |
se recomienda | 271 |
autoimmune diseases | 271 |
interferon beta | 271 |
medical care | 271 |
oropharyngeal swabs | 270 |
lung function | 270 |
sense rna | 270 |
analysis revealed | 270 |
positive rate | 270 |
asymptomatic infections | 270 |
proteolytic cleavage | 269 |
lamp assay | 269 |
healthy controls | 269 |
clinical evidence | 269 |
mild cases | 269 |
human igg | 269 |
invasive ventilation | 268 |
ct value | 268 |
cellular receptor | 268 |
systematic reviews | 268 |
physical distancing | 268 |
disease onset | 268 |
cell count | 267 |
protein sequence | 267 |
coronavirus nsp | 267 |
care providers | 267 |
swab specimens | 267 |
escherichia coli | 267 |
viral genomes | 267 |
ii receptor | 267 |
infection risk | 267 |
like sars | 267 |
therapeutic efficacy | 267 |
blood cells | 267 |
written informed | 266 |
case study | 266 |
sars pathogenesis | 266 |
urgently needed | 266 |
transcription factor | 266 |
pp ab | 265 |
test result | 265 |
older age | 265 |
bovine serum | 265 |
blood donors | 265 |
chronic kidney | 265 |
coronavirus pandemic | 265 |
related coronaviruses | 265 |
jurisdictional claims | 264 |
use authorization | 264 |
commons attribution | 264 |
published maps | 264 |
remains neutral | 264 |
supportive care | 264 |
nature remains | 264 |
institutional affiliations | 264 |
like coronavirus | 263 |
also shown | 263 |
phase iii | 263 |
pg ml | 262 |
asymptomatic sars | 262 |
intermediate hosts | 262 |
antibody detection | 262 |
significantly increased | 261 |
illness onset | 261 |
cov pl | 261 |
statistical analyses | 261 |
single cell | 261 |
wild type | 261 |
continuous variables | 261 |
transcription polymerase | 260 |
cycle threshold | 260 |
fatality rates | 260 |
cruise ship | 260 |
interquartile range | 260 |
term care | 260 |
genetic diversity | 259 |
elderly patients | 259 |
seafood market | 259 |
transmembrane serine | 259 |
der waals | 259 |
total rna | 259 |
old man | 258 |
coronavirus genome | 258 |
results show | 258 |
dependent manner | 258 |
diagnostic test | 258 |
pathogenic coronaviruses | 258 |
may explain | 258 |
twice daily | 258 |
protein structures | 258 |
invasive mechanical | 258 |
disease patients | 257 |
palm civets | 257 |
social media | 257 |
categorical variables | 257 |
clinical diagnosis | 257 |
molecular biology | 257 |
many patients | 257 |
intermediate host | 257 |
generated using | 256 |
will help | 256 |
hiv infection | 256 |
staff members | 256 |
infection rates | 256 |
inflammatory mediators | 255 |
healthcare system | 255 |
march th | 255 |
vascular endothelial | 254 |
compassionate use | 254 |
stool samples | 254 |
significantly associated | 254 |
soluble ace | 254 |
cerebrovascular disease | 254 |
respiratory secretions | 254 |
laboratory diagnosis | 254 |
human metapneumovirus | 254 |
wild animals | 254 |
lupus erythematosus | 254 |
fisher scientific | 253 |
syndrome associated | 253 |
surface stability | 253 |
medicinal plants | 253 |
nasal cannula | 252 |
health crisis | 252 |
generating procedures | 252 |
renal failure | 252 |
potential inhibitors | 252 |
aged years | 251 |
epi isl | 251 |
healthcare systems | 251 |
similar results | 251 |
clinical progression | 251 |
reproductive number | 251 |
bowel disease | 251 |
significantly different | 251 |
mammalian cells | 250 |
four patients | 250 |
smooth muscle | 250 |
care settings | 250 |
negative controls | 250 |
genomic characterization | 250 |
international concern | 250 |
human disease | 249 |
protein binding | 249 |
blood vessels | 249 |
northern italy | 249 |
magnetic resonance | 249 |
combination therapy | 249 |
testing positive | 248 |
mutation rate | 248 |
chronic diseases | 248 |
autodock vina | 248 |
well known | 248 |
environmental factors | 248 |
global public | 247 |
horseshoe bats | 247 |
first two | 247 |
aerosol transmission | 247 |
mhc class | 247 |
healthy donors | 247 |
exact test | 247 |
staphylococcus aureus | 247 |
cl protease | 247 |
prospective cohort | 246 |
long term | 246 |
rapidly spread | 246 |
potential drug | 246 |
immune function | 246 |
note springer | 246 |
protein sequences | 245 |
neutralizing activity | 245 |
interstitial pneumonia | 245 |
prostate cancer | 245 |
organ damage | 244 |
european countries | 244 |
dynamics simulations | 244 |
operating room | 244 |
medical conditions | 244 |
chloroquine phosphate | 243 |
confirmed case | 243 |
disease prevention | 243 |
studies suggest | 243 |
coronavirus receptor | 243 |
respiratory rate | 243 |
complement activation | 242 |
less severe | 242 |
higher viral | 242 |
cell subsets | 242 |
phase ii | 242 |
thrombotic complications | 242 |
con covid | 242 |
recently reported | 242 |
dimer levels | 242 |
corticosteroid treatment | 242 |
among children | 242 |
olfactory bulb | 242 |
small sample | 241 |
potential treatment | 241 |
eye protection | 241 |
epidemiological data | 241 |
virus spread | 241 |
inclusion criteria | 241 |
acid sequences | 241 |
data indicate | 240 |
cov plpro | 240 |
ct imaging | 240 |
respiratory coronavirus | 239 |
recent report | 239 |
cancer cells | 239 |
antiviral activities | 239 |
asymptomatic carrier | 239 |
mrna expression | 239 |
income countries | 239 |
older patients | 239 |
differentially expressed | 239 |
highly infectious | 239 |
data sets | 238 |
nsp protein | 238 |
predictive value | 238 |
por sars | 238 |
patients undergoing | 238 |
viral antigens | 238 |
critical covid | 238 |
bat species | 238 |
main proteinase | 238 |
systemic lupus | 238 |
working group | 237 |
much lower | 237 |
coronavirus entry | 237 |
entry receptor | 237 |
patients requiring | 237 |
retrospective analysis | 236 |
artificial intelligence | 236 |
like coronaviruses | 236 |
clinical study | 236 |
time point | 236 |
spread rapidly | 235 |
treatment strategies | 235 |
breast cancer | 235 |
deceased patients | 235 |
low viral | 235 |
new insights | 235 |
vitro antiviral | 235 |
cov may | 235 |
based drug | 235 |
biosafety level | 234 |
activation syndrome | 234 |
acid test | 234 |
normal range | 234 |
bronchial epithelial | 234 |
coronavirus envelope | 234 |
based vaccine | 234 |
brain barrier | 234 |
health services | 233 |
included studies | 233 |
seq data | 233 |
transmission routes | 233 |
serological testing | 233 |
virological assessment | 233 |
cell proliferation | 233 |
among different | 233 |
transport medium | 233 |
posted april | 232 |
syndrome virus | 232 |
death rate | 232 |
whether sars | 232 |
developing countries | 232 |
ocular surface | 232 |
therapeutic potential | 232 |
major outbreak | 232 |
mouse models | 232 |
ct scans | 231 |
data set | 231 |
vast majority | 231 |
confidence intervals | 231 |
supplemental oxygen | 231 |
suspected sars | 231 |
cell immunity | 230 |
recombinant sars | 230 |
hospital mortality | 230 |
acid amplification | 230 |
species transmission | 230 |
infected persons | 229 |
cause severe | 229 |
coronaviridae family | 229 |
highly sensitive | 228 |
host factors | 228 |
humoral immunity | 228 |
adults hospitalized | 228 |
like proteinase | 228 |
several limitations | 228 |
coronavirus papain | 228 |
studies reported | 227 |
transcription factors | 227 |
study conducted | 227 |
possible cause | 227 |
sars patient | 227 |
neutrophil extracellular | 227 |
dromedary camels | 227 |
convalescent patients | 227 |
severe infection | 227 |
cov infected | 227 |
tissue factor | 226 |
significant increase | 226 |
live attenuated | 226 |
basic reproduction | 226 |
odds ratio | 226 |
reference genome | 226 |
recent reports | 225 |
gi symptoms | 225 |
health concern | 225 |
recombinant human | 225 |
transmembrane domain | 225 |
comparative analysis | 225 |
goat anti | 224 |
first days | 224 |
related viruses | 224 |
primary care | 224 |
reactive oxygen | 224 |
storm syndromes | 224 |
blood mononuclear | 224 |
pilot study | 223 |
influenza vaccine | 223 |
fold higher | 223 |
will provide | 223 |
additional file | 223 |
secondary infections | 223 |
enzymatic activity | 222 |
lysis buffer | 222 |
african green | 222 |
healthcare personnel | 222 |
human host | 222 |
air pollution | 222 |
recombinant protein | 221 |
post infection | 221 |
infected vero | 221 |
protective role | 221 |
porcine epidemic | 221 |
emerging viruses | 221 |
neonates born | 220 |
transfected cells | 220 |
specimen collection | 220 |
live virus | 220 |
host proteins | 220 |
clinical research | 220 |
posted november | 220 |
cellular entry | 220 |
among others | 220 |
chest radiograph | 220 |
body fluids | 220 |
effective vaccine | 220 |
clinical presentations | 219 |
infected cases | 219 |
nasal swabs | 219 |
determined using | 219 |
health professionals | 219 |
convalescent sera | 219 |
dendritic cell | 218 |
coronavirus diseases | 218 |
extracellular traps | 218 |
liver function | 218 |
among health | 218 |
human body | 218 |
close proximity | 218 |
platelet count | 218 |
quality control | 218 |
patients suffering | 218 |
transmembrane protease | 218 |
systemic inflammatory | 218 |
enzyme inhibitors | 218 |
sequence similarity | 218 |
following sars | 217 |
lavage fluid | 217 |
immune evasion | 217 |
deep learning | 217 |
travel history | 216 |
human protein | 216 |
viral disease | 216 |
single center | 216 |
based vaccines | 216 |
viral fusion | 216 |
diagnostic accuracy | 215 |
cell infection | 215 |
antibody production | 215 |
inactive inactive | 215 |
feline infectious | 215 |
binding affinities | 215 |
med doi | 215 |
coronavirus vaccine | 214 |
structural analysis | 214 |
viral pathogens | 214 |
oxygen species | 213 |
respiratory support | 213 |
primary human | 213 |
diamond princess | 213 |
financial support | 213 |
infectious peritonitis | 213 |
accession number | 213 |
genetic material | 213 |
sequence data | 213 |
orf protein | 213 |
cell cycle | 212 |
moderate covid | 212 |
consider cytokine | 212 |
community outbreak | 212 |
breast milk | 212 |
generation sequencing | 212 |
direct viral | 211 |
like disease | 211 |
analysis using | 211 |
likely due | 211 |
potent inhibitor | 211 |
immune activation | 211 |
culture medium | 211 |
binding domains | 210 |
cell therapy | 210 |
host receptor | 210 |
increased mortality | 210 |
ic values | 209 |
two decades | 209 |
cysteine protease | 209 |
times higher | 208 |
also identified | 208 |
final concentration | 208 |
genomic sequences | 208 |
unclear whether | 207 |
species severe | 207 |
inflammatory diseases | 207 |
copy number | 207 |
clinical efficacy | 206 |
codon usage | 206 |
viral titers | 206 |
cases reported | 206 |
inactivated sars | 206 |
adverse outcomes | 206 |
hospital discharge | 206 |
pulmonary edema | 206 |
negative rt | 206 |
time period | 206 |
furin cleavage | 206 |
ex vivo | 205 |
membrane oxygenation | 205 |
available online | 205 |
qt interval | 205 |
affected patients | 205 |
within hours | 205 |
two distinct | 205 |
many studies | 205 |
antibody titer | 205 |
imaging features | 205 |
maximum likelihood | 205 |
mg day | 205 |
docking studies | 205 |
pcr positive | 204 |
underlying diseases | 204 |
pandemic caused | 204 |
host defense | 204 |
glass opacity | 204 |
among covid | 204 |
viral transport | 204 |
potential drugs | 204 |
beneficial effects | 204 |
wuhan clinical | 204 |
develop severe | 204 |
data regarding | 204 |
cov virus | 204 |
memory cd | 204 |
transcriptase polymerase | 203 |
ct images | 203 |
length human | 203 |
among healthcare | 203 |
fusion proteins | 203 |
available evidence | 203 |
decision making | 202 |
high rate | 202 |
family coronaviridae | 202 |
transplant patients | 202 |
dna vaccines | 202 |
patients diagnosed | 202 |
pneumonia cases | 202 |
well plate | 202 |
epidemic diarrhea | 202 |
cell membranes | 202 |
disease covid | 202 |
immune dysregulation | 202 |
will require | 201 |
may represent | 201 |
clinical use | 201 |
corticosteroid therapy | 201 |
three days | 201 |
probable cases | 201 |
negative samples | 201 |
drug target | 201 |
human cases | 201 |
studies using | 200 |
patients affected | 200 |
mildly symptomatic | 200 |
fecal samples | 200 |
immunocompromised patients | 200 |
severe lung | 200 |
five patients | 200 |
two studies | 200 |
severely affected | 200 |
binding energies | 200 |
prolonged viral | 200 |
virus detection | 200 |
target cell | 200 |
tcid ml | 199 |
increasing number | 199 |
human primates | 199 |
pathogenic human | 199 |
mg twice | 199 |
extracorporeal membrane | 199 |
reference sequence | 199 |
st century | 199 |
creatine kinase | 199 |
short period | 198 |
significant reduction | 198 |
yellow fever | 198 |
renal function | 198 |
epidemiological studies | 198 |
also detected | 198 |
hand washing | 198 |
household members | 198 |
study population | 198 |
host innate | 198 |
negative test | 198 |
hospital staff | 198 |
ongoing clinical | 198 |
six patients | 198 |
baseline characteristics | 197 |
single nucleotide | 197 |
flow nasal | 197 |
para el | 197 |
pulmonary function | 197 |
retrospective case | 197 |
barr virus | 197 |
endotracheal intubation | 197 |
coronavirus family | 197 |
emerging human | 196 |
molecular modeling | 196 |
cytokine storms | 196 |
cell epitope | 196 |
acute myocardial | 196 |
outcomes among | 196 |
safety profile | 196 |
replacement therapy | 196 |
per well | 195 |
effective antiviral | 195 |
bacterial infection | 195 |
infected cell | 195 |
narrative review | 195 |
water molecules | 195 |
influenza vaccination | 195 |
also important | 195 |
host range | 195 |
least days | 195 |
health interventions | 195 |
randomised controlled | 195 |
high throughput | 195 |
old male | 195 |
genomic sequence | 194 |
health literacy | 194 |
severe clinical | 194 |
differential diagnosis | 194 |
previously published | 194 |
sars pneumonia | 194 |
infections among | 193 |
pregnant patients | 193 |
master mix | 193 |
protein levels | 193 |
task force | 193 |
short time | 193 |
transplant recipient | 193 |
body weight | 193 |
national institutes | 193 |
igg levels | 193 |
nursing homes | 193 |
limited number | 193 |
nasal cavity | 193 |
san diego | 193 |
inflammasome activation | 192 |
supporting information | 192 |
patients presented | 192 |
older people | 192 |
airway epithelia | 192 |
precautionary measures | 192 |
like illness | 192 |
dna polymerase | 192 |
copies per | 192 |
low risk | 192 |
critical cases | 192 |
heptad repeat | 192 |
sars transmission | 192 |
like virus | 192 |
complement system | 191 |
membrane vesicles | 191 |
graphpad prism | 191 |
days prior | 191 |
sars cl | 191 |
rna binding | 190 |
diarrhea virus | 190 |
web server | 190 |
million cases | 190 |
based assay | 190 |
nucleotide sequence | 190 |
index patient | 190 |
drug interactions | 190 |
mechanisms underlying | 190 |
viral membrane | 190 |
may serve | 190 |
three cases | 190 |
will likely | 190 |
viral attachment | 190 |
linear regression | 190 |
corresponding author | 190 |
washington state | 190 |
medical personnel | 190 |
distancing measures | 189 |
health behaviors | 189 |
barre syndrome | 189 |
docking study | 189 |
olfactory epithelium | 189 |
induced acute | 189 |
potential target | 189 |
general hospital | 189 |
nucleocapsid proteins | 189 |
alveolar cells | 188 |
inflammatory effects | 188 |
label non | 188 |
detection rate | 188 |
physical examination | 188 |
also demonstrated | 188 |
type iii | 188 |
cumulative number | 188 |
plasminogen activator | 188 |
broad range | 188 |
plasma samples | 187 |
cells may | 187 |
may reduce | 187 |
therapeutic strategy | 187 |
parainfluenza virus | 187 |
modelling study | 187 |
essential role | 187 |
protein complex | 187 |
western blotting | 187 |
detecting sars | 187 |
potent neutralizing | 187 |
recent advances | 187 |
animal studies | 187 |
cystic fibrosis | 187 |
network analysis | 187 |
newly identified | 187 |
possible role | 187 |
new disease | 187 |
patients will | 187 |
radiological findings | 187 |
pneumonia caused | 187 |
protective measures | 187 |
rbd protein | 187 |
transmission rate | 186 |
relatively small | 186 |
protective effects | 186 |
viral infectivity | 186 |
artery disease | 186 |
fatal cases | 186 |
healthcare providers | 186 |
two major | 186 |
associated sars | 186 |
express ace | 186 |
ncov pneumonia | 186 |
high degree | 186 |
large numbers | 186 |
situ hybridization | 186 |
anal swabs | 185 |
recent years | 185 |
human covs | 185 |
umbilical cord | 185 |
ibd patients | 185 |
applied biosystems | 185 |
proteolytic processing | 185 |
infected individual | 185 |
multiorgan failure | 185 |
viral life | 185 |
new human | 185 |
coronavirus covid | 185 |
left ventricular | 185 |
virus genome | 184 |
inhibitory effects | 184 |
solid organ | 184 |
replication cycle | 184 |
clinical disease | 184 |
healthy adults | 184 |
one hand | 184 |
target protein | 184 |
inflammatory drugs | 184 |
care system | 184 |
two days | 184 |
critical patients | 184 |
highly specific | 184 |
wide variety | 184 |
rbd domain | 184 |
treated patients | 183 |
ace activity | 183 |
disease pathogenesis | 183 |
european society | 183 |
day post | 183 |
virus neutralization | 183 |
three groups | 183 |
among sars | 183 |
receptor antagonist | 183 |
therapeutic option | 183 |
first identified | 183 |
mortality due | 183 |
cov rbd | 183 |
killer cells | 183 |
targeting sars | 182 |
ace levels | 182 |
chest radiographs | 182 |
limited data | 182 |
binding motif | 182 |
false positives | 182 |
environmental conditions | 182 |
protein synthesis | 182 |
clinical benefit | 182 |
table shows | 182 |
deaths worldwide | 182 |
stimulating factor | 182 |
emergency response | 182 |
also tested | 181 |
based study | 181 |
con el | 181 |
clinical severity | 181 |
chest pain | 181 |
future research | 181 |
high fever | 181 |
different cell | 181 |
au ml | 181 |
vitro activity | 181 |
buffered saline | 181 |
regression model | 181 |
death toll | 181 |
serially diluted | 181 |
molecular mechanism | 180 |
domain complexed | 180 |
th day | 180 |
id now | 180 |
expression level | 180 |
young adults | 180 |
medical treatment | 180 |
long time | 180 |
atrial fibrillation | 180 |
drug repositioning | 180 |
based assays | 180 |
lymphocyte counts | 180 |
long structural | 180 |
april th | 180 |
worth noting | 180 |
hla class | 180 |
vesicular stomatitis | 180 |
social isolation | 179 |
still unclear | 179 |
coagulation parameters | 179 |
viral pathogenesis | 179 |
side chains | 179 |
igm igg | 179 |
new england | 179 |
transport media | 179 |
health officials | 179 |
humoral response | 179 |
major role | 179 |
lung diseases | 179 |
time course | 178 |
murine hepatitis | 178 |
extracellular vesicles | 178 |
article distributed | 178 |
also associated | 178 |
room air | 178 |
oropharyngeal swab | 178 |
chronic hepatitis | 178 |
novel severe | 178 |
sex differences | 178 |
information regarding | 178 |
cumulative incidence | 178 |
organ transplant | 178 |
emerging infections | 178 |
sequence homology | 178 |
study using | 177 |
inflammatory cells | 177 |
authors contributed | 177 |
hiv protease | 177 |
patients developed | 177 |
clinically approved | 177 |
blood glucose | 177 |
coronavirus isolated | 177 |
cohort studies | 177 |
different regions | 177 |
contact history | 177 |
severe forms | 177 |
nuclear factor | 177 |
membrane proteins | 177 |
will continue | 177 |
remains unknown | 177 |
imaging findings | 176 |
higher affinity | 176 |
inhibitors targeting | 176 |
lymphocyte subsets | 176 |
high incidence | 176 |
patients compared | 176 |
potential targets | 176 |
throughput screening | 176 |
essential oils | 176 |
one week | 176 |
large scale | 176 |
acid testing | 176 |
increased expression | 176 |
data available | 176 |
mild respiratory | 176 |
quantitative rt | 175 |
assessed using | 175 |
diabetic patients | 175 |
like proteases | 175 |
se ha | 175 |
cov entry | 175 |
heart rate | 175 |
del paciente | 175 |
molecule inhibitors | 175 |
interferon response | 175 |
chest computed | 175 |
showed significant | 175 |
ii pneumocytes | 175 |
environmental contamination | 174 |
also present | 174 |
human serum | 174 |
infectious sars | 174 |
affected countries | 174 |
expression vector | 174 |
study demonstrated | 174 |
health response | 174 |
emerging viral | 174 |
data collected | 174 |
cov outbreak | 174 |
pathogenic coronavirus | 174 |
preliminary results | 174 |
measured using | 173 |
south africa | 173 |
first report | 173 |
access article | 173 |
old woman | 173 |
antiviral agent | 173 |
associated case | 173 |
posterior oropharyngeal | 173 |
retrospective review | 173 |
although sars | 173 |
lung fibrosis | 173 |
several countries | 173 |
covid patients | 173 |
differential expression | 173 |
cytokine levels | 173 |
specific igm | 173 |
bacterial infections | 173 |
blot analysis | 172 |
dynamics simulation | 172 |
mediated immunity | 172 |
fold increase | 172 |
current status | 172 |
el uso | 172 |
sars vaccine | 172 |
day mortality | 172 |
abnormal coagulation | 172 |
flow rate | 171 |
patients recovered | 171 |
cell lysates | 171 |
analytical sensitivity | 171 |
infected patient | 171 |
ge healthcare | 171 |
global spread | 171 |
ncov infected | 171 |
surface glycoprotein | 171 |
nasal swab | 171 |
ifn response | 171 |
psychological distress | 171 |
human immune | 171 |
muscle cells | 171 |
many cases | 171 |
lower risk | 171 |
chest radiography | 171 |
virus load | 171 |
subunit vaccine | 171 |
become infected | 171 |
symptoms onset | 170 |
virus shedding | 170 |
million confirmed | 170 |
virus titers | 170 |
target proteins | 170 |
airway epithelium | 170 |
health status | 170 |
face shield | 170 |
nucleotide sequences | 170 |
secondary antibody | 169 |
natural reservoirs | 169 |
case definitions | 169 |
ligand binding | 169 |
newly discovered | 169 |
study protocol | 169 |
tmprss expression | 169 |
cell counts | 169 |
molecular testing | 169 |
near future | 169 |
plasma levels | 168 |
asymptomatic contact | 168 |
por covid | 168 |
obtained using | 168 |
mortality among | 168 |
ifn production | 168 |
standard care | 168 |
liver transplant | 168 |
chinese horseshoe | 168 |
serial dilutions | 168 |
stomatitis virus | 168 |
bat cov | 168 |
cellular immunity | 168 |
independent risk | 168 |
antiviral compounds | 168 |
receptor usage | 167 |
signal transduction | 167 |
pattern recognition | 167 |
higher rates | 167 |
final manuscript | 167 |
i interferons | 167 |
substrate binding | 167 |
physical activity | 167 |
submitted work | 167 |
oropharyngeal saliva | 167 |
viral antigen | 167 |
therapeutic interventions | 167 |
nsp nsp | 167 |
enrichment analysis | 167 |
full text | 166 |
significant role | 166 |
fever virus | 166 |
clinical picture | 166 |
financial relationships | 166 |
drug resistance | 166 |
nonhuman primates | 166 |
gastroenteritis virus | 166 |
serological assay | 166 |
psychological impact | 166 |
inactivated vaccine | 166 |
igg igm | 166 |
genetic variants | 166 |
expression profiling | 166 |
include fever | 166 |
unknown etiology | 165 |
princess cruise | 165 |
positive cells | 165 |
two consecutive | 165 |
current sars | 165 |
vaccine construct | 165 |
cov clpro | 165 |
higher level | 165 |
case patient | 165 |
patients also | 165 |
different stages | 165 |
multiplex pcr | 165 |
original author | 165 |
sodium hypochlorite | 165 |
reported symptoms | 165 |
causes severe | 165 |
drug treatment | 165 |
ongoing pandemic | 165 |
control strategies | 164 |
syndrome clinical | 164 |
takes place | 164 |
cd cells | 164 |
rapid test | 164 |
protein complexes | 164 |
gel electrophoresis | 164 |
testing capacity | 164 |
negative sars | 164 |
neuroinvasive potential | 164 |
por el | 164 |
potential antiviral | 164 |
second week | 164 |
spike glycoproteins | 164 |
different species | 163 |
palm civet | 163 |
rhesus macaque | 163 |
naturally occurring | 163 |
encephalitis virus | 163 |
clinical application | 163 |
potential conflict | 163 |
randomized trial | 163 |
heparan sulfate | 163 |
full length | 163 |
confirmed patients | 163 |
asymptomatic covid | 163 |
th cells | 163 |
secondary cases | 162 |
viruses including | 162 |
cardiovascular complications | 162 |
based approach | 162 |
results indicated | 162 |
etiological agent | 162 |
false negatives | 162 |
molecular patterns | 162 |
associated molecular | 162 |
rapid review | 162 |
promising results | 162 |
local transmission | 162 |
functional characterization | 162 |
research team | 162 |
skeletal muscle | 162 |
insulin resistance | 162 |
thank dr | 162 |
ace cells | 161 |
healthy volunteers | 161 |
kg day | 161 |
virus strain | 161 |
lower levels | 161 |
infectious agent | 161 |
pathogenic viruses | 161 |
vital signs | 161 |
since sars | 161 |
root mean | 160 |
american college | 160 |
molecular basis | 160 |
transmission route | 160 |
diagnostic methods | 160 |
china covid | 160 |
worse outcomes | 160 |
nursing home | 160 |
patients died | 160 |
two independent | 159 |
studies will | 159 |
acute cardiac | 159 |
probe sets | 159 |
positive pcr | 159 |
future outbreaks | 159 |
also included | 159 |
veroe cells | 159 |
pcr products | 159 |
human populations | 159 |
negative result | 159 |
may require | 159 |
mice immunized | 159 |
disease spread | 159 |
pao fio | 159 |
clinical laboratory | 159 |
face shields | 158 |
identify potential | 158 |
mean square | 158 |
recent insights | 158 |
genbank accession | 158 |
fetal bovine | 158 |
digestive system | 158 |
el paciente | 158 |
prothrombin time | 158 |
bcg vaccination | 158 |
much less | 158 |
vascular permeability | 158 |
alanine aminotransferase | 158 |
medical research | 158 |
using different | 158 |
ace complex | 158 |
consensus statement | 158 |
patients reported | 158 |
cell viability | 158 |
may need | 157 |
negatively charged | 157 |
cytopathic effects | 157 |
clinical manifestation | 157 |
genome replication | 157 |
gastrointestinal manifestations | 157 |
approved drug | 157 |
recognition receptors | 157 |
ethical approval | 157 |
international health | 157 |
per million | 157 |
treatment protocol | 157 |
protease activity | 157 |
human influenza | 157 |
reverse genetics | 157 |
receptor expression | 157 |
advanced age | 157 |
may induce | 157 |
human subjects | 156 |
th march | 156 |
population density | 156 |
old female | 156 |
genetic recombination | 156 |
stromal cells | 156 |
clinical evaluation | 156 |
supplementary information | 156 |
inhibiting sars | 156 |
health conditions | 156 |
rna dependent | 156 |
acute infection | 156 |
pcr amplification | 155 |
may act | 155 |
spread worldwide | 155 |
included patients | 155 |
specific treatment | 155 |
severe pulmonary | 155 |
mini kit | 155 |
therapeutic intervention | 155 |
ucsf chimera | 155 |
supplementary materials | 155 |
proximal origin | 154 |
acute renal | 154 |
patients tested | 154 |
greater risk | 154 |
health organisation | 154 |
secondary infection | 154 |
test positive | 154 |
local health | 154 |
using human | 154 |
serum albumin | 154 |
ace mrna | 154 |
well established | 154 |
therapeutic approaches | 154 |
virus strains | 153 |
high number | 153 |
multicenter study | 153 |
system inhibitors | 153 |
may reflect | 153 |
male sex | 153 |
positivity rate | 153 |
virus clearance | 153 |
liver enzymes | 153 |
assay using | 153 |
glycosylation sites | 153 |
infants born | 153 |
cytoplasmic tail | 153 |
different human | 153 |
mass index | 153 |
literature search | 153 |
protein may | 152 |
viruses related | 152 |
specific antiviral | 152 |
pivotal role | 152 |
different time | 152 |
considered statistically | 152 |
receptor signaling | 152 |
antiphospholipid antibodies | 152 |
conformational change | 152 |
nasal epithelial | 152 |
mitigation strategies | 152 |
associated acute | 152 |
virus isolation | 152 |
spread across | 152 |
ec values | 152 |
care facility | 152 |
infections caused | 151 |
aspartate aminotransferase | 151 |
data show | 151 |
healthcare facilities | 151 |
cell receptors | 151 |
two main | 151 |
scientific evidence | 151 |
lung failure | 151 |
low level | 151 |
primer probe | 151 |
genome structure | 151 |
binding proteins | 151 |
stimulated gene | 151 |
human infections | 151 |
highly potent | 151 |
severe influenza | 151 |
higher rate | 151 |
conducted using | 151 |
since december | 151 |
risk patients | 150 |
existing drugs | 150 |
take place | 150 |
stress disorder | 150 |
second wave | 150 |
pulmonary inflammation | 150 |
immune systems | 150 |
terminal region | 150 |
huanan seafood | 150 |
arterial hypertension | 150 |
done using | 150 |
science foundation | 150 |
ncov sars | 150 |
novel therapeutic | 150 |
induced apoptosis | 150 |
cov orf | 150 |
clinical information | 150 |
least three | 150 |
term outcomes | 150 |
high dose | 150 |
personal protection | 150 |
johns hopkins | 150 |
nonhuman primate | 150 |
cell function | 150 |
chest imaging | 150 |
coronavirus study | 149 |
isolation ward | 149 |
expressed genes | 149 |
high specificity | 149 |
study covid | 149 |
commons licence | 149 |
particularly important | 149 |
detection limit | 149 |
pcr detection | 149 |
domestic animals | 149 |
carrier transmission | 149 |
subcellular localization | 149 |
different populations | 149 |
detected using | 149 |
chemoattractant protein | 149 |
first line | 149 |
health threat | 149 |
rhesus monkeys | 149 |
intrauterine vertical | 149 |
experimental data | 149 |
expression data | 149 |
inhibit viral | 148 |
previous sars | 148 |
across different | 148 |
exclusion criteria | 148 |
studies show | 148 |
diagnostic assays | 148 |
cells using | 148 |
sars survivors | 148 |
may th | 148 |
severe critical | 148 |
health service | 147 |
also performed | 147 |
preliminary data | 147 |
samples obtained | 147 |
convalescent individuals | 147 |
toronto area | 147 |
surveillance system | 147 |
positively charged | 147 |
igm antibody | 147 |
vivo studies | 147 |
nosocomial infection | 147 |
laboratory data | 147 |
expression patterns | 147 |
disease clinical | 147 |
tertiary care | 147 |
developed symptoms | 147 |
also suggested | 147 |
still unknown | 147 |
storm syndrome | 147 |
chinese government | 147 |
imported cases | 147 |
highly effective | 147 |
protein induces | 146 |
prevent sars | 146 |
several days | 146 |
epidemiological features | 146 |
body mass | 146 |
mediated immune | 146 |
potent antiviral | 146 |
antigen presentation | 146 |
natural history | 146 |
healthcare worker | 146 |
people worldwide | 146 |
np swab | 146 |
blood flow | 146 |
following infection | 146 |
causing severe | 146 |
published studies | 146 |
step rt | 146 |
central role | 145 |
human neutralizing | 145 |
clinical laboratories | 145 |
care systems | 145 |
south america | 145 |
rapidly evolving | 145 |
droplet transmission | 145 |
symptomatic covid | 145 |
cutaneous manifestations | 145 |
supplementary data | 145 |
tissue samples | 144 |
plasmid dna | 144 |
risk groups | 144 |
cord blood | 144 |
thromboembolic events | 144 |
candidate vaccines | 144 |
potent inhibitors | 144 |
taste disorders | 144 |
monocyte chemoattractant | 144 |
computational methods | 144 |
hypercoagulable state | 144 |
published data | 144 |
drug delivery | 144 |
olfactory dysfunction | 144 |
among people | 144 |
first day | 144 |
symptomatic individuals | 144 |
several factors | 144 |
host interactions | 144 |
ongoing covid | 144 |
accessory protein | 144 |
virus vaccine | 143 |
necrotizing encephalopathy | 143 |
rapid diagnosis | 143 |
digestive tract | 143 |
nine pregnant | 143 |
oral mucosa | 143 |
several clinical | 143 |
antiviral immunity | 143 |
data obtained | 143 |
significant impact | 143 |
ace may | 143 |
potential use | 143 |
malayan pangolins | 143 |
samples tested | 143 |
coronavirus epidemic | 142 |
family member | 142 |
environmental surfaces | 142 |
amniotic fluid | 142 |
global initiative | 142 |
host species | 142 |
among hospitalized | 142 |
past years | 142 |
antiviral responses | 142 |
years ago | 142 |
effective vaccines | 142 |
viral particle | 142 |
novel coronaviruses | 142 |
droplet nuclei | 142 |
temporal profiles | 142 |
surface plasmon | 142 |
poor outcomes | 142 |
high proportion | 142 |
ace interaction | 142 |
overall mortality | 142 |
moderate coronavirus | 142 |
different clinical | 142 |
communicable diseases | 142 |
many viruses | 142 |
metabolic syndrome | 142 |
important roles | 142 |
fusion core | 141 |
cells transfected | 141 |
using molecular | 141 |
coronavirus nonstructural | 141 |
competing financial | 141 |
two viruses | 141 |
greater toronto | 141 |
online version | 141 |
human bronchial | 141 |
binding mode | 141 |
review article | 141 |
risk group | 141 |
serum creatinine | 141 |
cov strains | 141 |
immunofluorescence assay | 141 |
lung involvement | 141 |
ischaemic stroke | 141 |
per minute | 141 |
infection caused | 141 |
will allow | 141 |
mouse igg | 141 |
presumed asymptomatic | 141 |
performance characteristics | 141 |
human cov | 141 |
human beings | 140 |
molecular evolution | 140 |
pulmonary vascular | 140 |
containment measures | 140 |
psychiatric disorders | 140 |
well tolerated | 140 |
viral activity | 140 |
infection causes | 140 |
asian countries | 140 |
thrombotic events | 140 |
another important | 140 |
patients clinical | 140 |
natural reservoir | 140 |
rapid development | 140 |
alveolar type | 140 |
highest number | 140 |
inflammatory factors | 140 |
cov antibody | 139 |
molecular detection | 139 |
positively correlated | 139 |
liver damage | 139 |
shed light | 139 |
catalytic activity | 139 |
also called | 139 |
allowed us | 139 |
severe outcomes | 139 |
new zealand | 139 |
care testing | 139 |
cov proteins | 139 |
test performance | 139 |
proinflammatory cytokine | 139 |
electrostatic interactions | 139 |
system involvement | 139 |
newly emerging | 139 |
primary outcome | 139 |
mice transgenic | 139 |
one month | 139 |
using rt | 139 |
readily available | 139 |
sars case | 139 |
lesser extent | 139 |
pulmonary pathology | 138 |
increased susceptibility | 138 |
subunit vaccines | 138 |
one day | 138 |
mycobacterium tuberculosis | 138 |
phase trial | 138 |
higher proportion | 138 |
average age | 138 |
rdrp gene | 138 |
cultured cells | 138 |
less common | 138 |
comparative study | 138 |
kj mol | 138 |
supplemental table | 138 |
hospitalised patients | 138 |
treating patients | 138 |
spinal cord | 138 |
infected animals | 138 |
replication complex | 138 |
novel corona | 138 |
genetic analysis | 138 |
serial interval | 138 |